Development of a ¹⁶¹Tb-based radiopharmaceutical for melanoma
No Thumbnail Available
Authors
Meeting name
Sponsors
Date
Journal Title
Format
Thesis
Subject
Abstract
[EMBARGOED UNTIL 12/01/2026] Melanoma continues to represent a disease with a high number of mortalities despite the clinical interventions, improvements in its diagnosis, and the different avenues of treatment; the incidence of total remission continues to be low. There is a pressing need for other treatment modalities and a combination of modalities for treatment. Targeted radiopharmaceuticals represent one of these modalities that hold the potential for diagnosing and treating diseases such as cancer. This work presents the preparation and characterization of two ¹⁶¹Tb radiolabeled radiopharmaceuticals which are developed with an aim to be used in the treatment of VLA-4 positive melanoma due to the emission properties of ¹⁶¹Tb (β-, Auger, and conversion electrons). Data on the radiosynthesis, Log D₇.₄, and serum stability of both radiotracers are presented and discussed in this study.
Table of Contents
PubMed ID
Degree
M.S.